DIAGNOSTICS FOR THE REAL WORLD LIMITED
Medtech · Private
point-of-care nucleic acid amplification test (SAMBA II system) for detecting Hepatitis C RNA from finger-prick blood
drw-ltd.com →- Grants
- $3.4M
- 4 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $6.5M
- 1 award · Health and Human S
- #96 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal contract | Department of Health and Human Services · This Contract Award Is For The Development Of A Rapid Hiv Point-of-care Diagnostic Device For Resource-limited Settings | $6,533,490 | |
| Federal grant | Department of Health and Human Services · Phase II · SAMBA HIV-1 Semi-quantitative whole blood test for resource limited settings | $951,508 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Commercial Readiness for SAMBA HIV Whole Blood Semi Quantitative Test for Resource Limited Settings | $907,877 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of two simple and robust point-of-care assays for detection and therapy monitoring of hepatitis B in resource-limited settings | $1,358,849 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a simple and robust point-of-care test for detection of Hepatitis C RNA from finger prick whole blood in resource-limited settings | $143,627 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 93 | Veracyte | $6.8M | $22M |
| 94 | SONIVATE MEDICAL, INC. | $6.7M | $1.4M |
| 95 | AMSEL MEDICAL CORPORATION | $6.6M | $40K |
| 96 | DIAGNOSTICS FOR THE REAL WORLD LIMITED | $6.5M | — |
| 97 | CVD EQUIPMENT CORPORATION | $6.5M | — |
| 98 | AccuVein Inc. | $6.4M | $48M |
| 99 | IFYBER LLC | $6.3M | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.